Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00768989 · ClinicalTrials.gov registry record · Phase 2
Phase IIB Pilot of Atazanavir + Raltegravir
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 167
- Enrollment target
NCT00768989 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 167 participants.
The verdict
NCT00768989, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 167 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of atazanavir and raltegravir taken together is safe and effective in the treatment of human immunodeficiency virus (HIV).
Interventions
- DRUG Ritonavir
- DRUG Atazanavir
- DRUG Raltegravir
- DRUG Tenofovir/Emtricitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00768989
The ClinicalTrials.gov registry entry for NCT00768989 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 167 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ritonavir is the first listed.
NCT00768989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00768989 about?
NCT00768989 is a clinical study titled "Phase IIB Pilot of Atazanavir + Raltegravir". The purpose of this study is to determine if the combination of atazanavir and raltegravir taken together is safe and effective in the treatment of human immunodeficiency virus (HIV).
What is the current status of trial NCT00768989?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 167 participants. The study started on 2008-11. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00768989?
The interventions under investigation include: Ritonavir (DRUG), Atazanavir (DRUG), Raltegravir (DRUG), Tenofovir/Emtricitabine (DRUG).
Who is sponsoring clinical trial NCT00768989?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.